Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-950-4 | CAS number: 3290-92-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
In three recent in vitro GLP studies conducted according to OECD guidelines, TMPTMA was found negative in bacterial reverse mutation test and mammalian gene mutation assay (HPRT) and was found positive in chromosome aberration test on human lymphocytes only in presence of metabolic activation.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From May 20 to June 25, 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- Not applicable
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- Aroclor 1254 induced rat liver post-mitochondrial fraction (S-9), obtained from Molecular Toxicology Incorporated, USA
- Test concentrations with justification for top dose:
- - Range-finder experiment and experiment 1: 1.6, 8, 40, 200, 1000 and 5000 µg/plate (with and without S-9)
- Experiment 2: 156.3, 312.5, 625, 1250, 2500 and 5000 µg/plate (with and without S-9) - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Dimethyl sulphoxide (DMSO)
- Justification for choice of solvent/vehicle: Solubility of propylidynetrimethyl trimethacrylate in DMSO = 100 mg/mL - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: See table 1
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: Plate incorporation method; as the results of Experiment 1 were negative, treatments in the presence of S-9 in experiment 2 included a pre-incubation step (incubation for 1 hour at 37±1°C).
DURATION
For all assays, bacteria were cultured at 37±1°C for 10 hours in nutrient broth, containing ampicillin (TA98, TA100) or ampicillin and tetracycline (TA102) as appropriate. Incubation was carried out with shaking in an anhydric incubator. All treatments were completed within 6 hours of the end of the incubation period.
After plating with test substance or control, the plates were inverted and incubated at 37±1°C in the dark for 3 days.
SELECTION AGENT (mutation assays): histidine
NUMBER OF REPLICATIONS:
Range-finding test: triplicate plates; negative (vehicle) and positive controls were included in quintuplicate and triplicate, respectively.
Main experiments: triplicate plates; negative (vehicle) controls were included in quintuplicate, and positive controls were included in triplicate.
DETERMINATION OF CYTOTOXICITY
- Method: reduction in the number of revertants; thinning of background bacterial lawn. - Evaluation criteria:
- For valid data, the test article was considered to be mutagenic if:
- Dunnett's test gave a significant response (p=< 0.01) which was concentration related
- The positive trend/effects described above were reproducible.
Negative: If all of the above criteria were not met - Statistics:
- Dunnett's test was used to compare the counts at each concentration with the control. The presence or otherwise of a concentration response was checked by non-statistical analysis, up to limiting levels.
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Marked reduction in revertant numbers was observed at 2500 µg/plate and above in the presence of S-9
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Marked reduction in revertant numbers was observed at 2500 µg/plate and above in the presence of S-9 and at 5000 µg/plate in the absence of S-9
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- Precipitation of the test article was observed on all test plates treated at 5000 µg/plate in the Range-Finder Experiment and Experiment 1 and at 2500 µg/plate and above in Experiment 2.
In the range-finder experiment and in experiment 1, no evidence of toxicity was observed as would normally manifest as a diminution of the background bacterial lawn or a marked reduction in revertant numbers.
In the second experiment, evidence of toxicity in the form of a marked reduction in revertant numbers was observed at 2500 µg/plate and above in strains TA1535 and TA1537 in the presence of S-9 and at 5000 µg/plate in strain TA1537 in the absence of S-9. - Conclusions:
- Under the test conditions, propylidynetrimethyl trimethacrylate is not considered as mutagenic in this bacterial system according to the criteria of the Annex VI to the Directive 67/548/EEC and CLP Regulation(EC) N° (1272-2008).
- Executive summary:
In a GLP study performed according to OECD guideline 471, propylidynetrimethyl trimethacrylate was tested for mutagenicity using Salmonella typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102 with the plate incorporation and preincubation methods in the presence and absence of metabolic activation system (S-9 mix). Due to absence of toxicity in the range-finder test, using TA100 tested at concentrations of 1.6, 8, 40, 200, 1000 and 5000 µg/plate with and without S-9, all strains in experiment 1 were tested with and without S-9 at these concentrations. In order to examine more closely those concentrations of propylidynetrimethyl trimethacrylate approaching the maximum test concentration, the following concentrations were tested in the second experiment (using the preincubation method (1h at 37°C) when S-9 was used): 156.3, 312.5, 625, 1250, 2500 and 5000 µg/plate, with and without S-9. Precipitation of the test article was observed on all test plates treated at 5000 µg/plate in the Range-Finder Experiment and Experiment 1 and at 2500 µg/plate and above in Experiment 2. In the range-finder experiment and in experiment 1, no evidence of toxicity was observed as would normally manifest as a diminution of the background bacterial lawn or a marked reduction in revertant numbers. In the second experiment, evidence of toxicity in the form of a marked reduction in revertant numbers was observed at 2500 µg/plate and above in strains TA1535 and TA1537 in the presence of S-9 and at 5000 µg/plate in strain TA1537 in the absence of S-9. The positive controls induced the appropriate responses in the corresponding strains. Propylidynetrimethyl trimethacrylate showed no substantial increases in revertant colony numbers over control count obtained with any of the tester strains at any concentrations in either presence or absence of S-9. Under the test conditions, propylidynetrimethyl trimethacrylate is not considered as mutagenic in this bacterial system.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 3 June 2010 - 6 July 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Target gene:
- Not applicable
- Species / strain / cell type:
- lymphocytes: human
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 fractions of rat liver microsomes induced by Aroclor 1254 (Molecular Toxicology Incorporated, USA)
- Test concentrations with justification for top dose:
- Range-finding test: from 2.902 to 800.0 µg/mL
Main experiment: without S9: 40, 50, 60, 70, 80, 90, 100, 140, 180 and 250 µg/mL; with S9: 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 650 and 800 µg/mL. - Vehicle / solvent:
- Dimethylsulfoxide (DMSO)
- Untreated negative controls:
- other: not applicable
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- other: not applicable
- Positive controls:
- yes
- Positive control substance:
- other: - without S9 mix: 4-Nitroquinoline 1-oxide (NQO), 2.5 and 5 µg/mL, - with S9 mix: cyclophosphamide at 10, 20 and 30 µg/mL
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium (HEPES-buffered RPMI medium containing 20% (v/v) heat inactivated foetal calf serum and 50 µg/mL gentamycin)
DURATION
- Exposure duration: 3 h with and without S9; 20 h without S9
- Expression time (cells in growth medium): 17 h after the 3-h treatment;
- Fixation time (start of exposure up to harvest of cells): 20 h
STAIN (for cytogenetic assays): Giemsa
NUMBER OF REPLICATIONS: 1.5 normal cell cycles
NUMBER OF CELLS EVALUATED: analysis of 200 metaphases/dose-level, with 100 metaphases/culture whenever possible.
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index
OTHER EXAMINATIONS:
- metaphase gaps, chromatid and chromosome breaks and exchanges, and others (multiple aberrations and pulverisations)
- Determination of polyploidy: yes
- Determination of endoreplication: yes - Evaluation criteria:
- For valid data, the test article was considered to induce clastogenic events if:
1. A proportion of cells with structural aberrations at one or more concentrations that exceeded the normal range was observed in both replicate cultures
2. A statistically significant increase in the proportion of cells with structural aberrations (excluding gaps) was observed (p = 0.05)
3. There was a concentration-related trend in the proportion of cells with structural aberrations (excluding gaps).
The test article was considered as positive in this assay if all of the above criteria were met. The test article was considered as negative in this assay if none of the above criteria were met.
Results which only partially satisfied the above criteria were dealt with on a case-by-case basis. - Statistics:
- The statistical significance of increases in the percentage of cells with structural aberrations for any data set was only taken into consideration if the frequency of aberrant cells in both replicate cultures at one or more concentrations exceeds the normal range. The statistical method used was Fisher's exact test.
- Species / strain:
- lymphocytes: Human
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Species / strain:
- lymphocytes: Human
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
No marked changes in osmolality or pH were observed at the highest concentration tested (800.0 µg/mL), compared to the concurrent vehicle controls.
ADDITIONAL INFORMATION ON CYTOTOXICITY AND PRECIPITATION: see tables 1 and 2 - Conclusions:
- Under these experimental conditions, propylidynetrimethyl trimethacrylate did not induce chromosome aberrations in cultured human lymphocytes without metabolic activation but induced chromosome aberrations in cultured human lymphocytes with metabolic activation.
- Executive summary:
In an in vitro chromosome aberration test performed according to OECD guideline 473 and in compliance with GLP, human primary lymphocytes were exposed to propylidynetrimethyl trimethacrylate dissolved in DMSO.
In a range-finding experiment, human lymphocyte cultures prepared from the pooled blood of three female donors were exposed to the test item for 3 h, with or without S9, or for 20 h without S9. Cells exposed for 3 h were harvested 20 h after the beginning of the treatment. Twelve concentrations were tested in the range of 2.902 - 800.0 µg/mL.
In the main experiment, cells were exposed for 3 h with or without S9, then rinsed and harvested 20 h after the beginning of the treatment.Concentrations from 40 to 250 µg/mL were tested without S9 and concnetrations from 50 to 800 µg/mL were tested with S9.
Positive controls (4-Nitroquinoline 1-oxide without S9 and cyclophosphamide with S9) induced the appropriate response.
Treatment of cells with propylidynetrimethyl trimethacrylate without S9 in the main experiment resulted in frequencies of cells with structural aberrations that were generally similar to those observed in concurrent vehicle control cultures for all concentrations analysed. Numbers of aberrant cells (excluding gaps) in treated cultures fell within the normal range with the exception of one culture at the lowest concentration analysed (80.00 µg/mL). However, the aberration frequency (excluding gaps) in the replicate culture at this concentration and at the two higher concentrations fell within the normal range; therefore this isolated observation was not considered biologically relevant.
Treatment in the presence of S-9 resulted in frequencies of cells with structural aberrations that were significantly higher (p = 0.001) than those observed in concurrent vehicle control cultures at the highest two concentrations analysed (650.0 and 800.0 µg/mL). Numbers of aberrant cells (excluding gaps) exceeded the normal range in one culture at the lowest concentration analysed (350.0 µg/mL) and in both cultures at 650.0 and 800.0 µg/mL and there was clear evidence of a concentration-related response.
No increases in the frequency of cells with numerical aberrations were observed with and without S9.
Under the test conditions, propylidynetrimethyl trimethacrylate was not clastogenic in human lymphocytes exposed in vitro without metabolic activation but was clastogenic in presence of metabolic activation.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 June 2010 to August 2010
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- HPRT
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Source of cells: Dr Donald Clive, Burroughs Wellcome Co. Cells
- Type and identity of media: RPMI 1640 medium
RPMI A: Penicillin (100 units/mL), streptomycin (100 µg/mL), amphotericin B (2.5 µg/mL) and pluronic acid (0.5 mg/mL)
RPMI 10: Horse serum (heat inactivated, 10% v/v), penicillin (100 units/mL), streptomycin (100 µg/mL), amphotericin B (2.5 µg/mL) and pluronic acid (0.5 mg/mL)
RPMI 20: Horse serum (heat inactivated, 20% v/v), penicillin (100 units/mL), streptomycin (100 µg/mL) and amphotericin B (2.5 µg/mL)
- Properly maintained: Yes
- Periodically checked for Mycoplasma contamination: Yes
- Periodically checked for karyotype stability: No data
- Periodically "cleansed" against high spontaneous background: Yes; each batch was purged of TK- mutants - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- 2% S9 fraction of Aroclor 1254-induced male Sprague-Dawley rats
- Test concentrations with justification for top dose:
- Range-finder experiment: 0, 105.6, 211.3, 422.5 and 845 µg/mL (with and without S-9)
Main study:
- Experiment 1: without S-9: 0, 30, 60, 90, 120 and 150 µg/mL; with S-9: 0, 100, 200, 250, 300, 350, 400 and 450 µg/mL
- Experiment 2: without S-9: 0, 30, 50, 70, 90 and 110 µg/mL; with S-9: 0, 100, 150, 200, 300, 350, 400, 450 and 500 µg/mL - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: dimethyl sulphoxide (DMSO)
- Justification for choice of solvent/vehicle: test material was poorly soluble in aqueous solutions - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- Remarks:
- with metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- Remarks:
- without metabolic activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 3 hours, 37 ± 1 ºC
- Expression time (cells in growth medium): 7 days, 37 ± 1 ºC in a humidified incubator gassed with 5 % v/v CO2 in air
- Selection time (if incubation with a selection agent): 12-13 days, 37 ± 1 ºC in a humidified incubator gassed with 5 % v/v CO2 in air
SELECTION AGENT (mutation assays): 6-thioguanine (6TG)
NUMBER OF REPLICATIONS: Duplicates (single cultures only used for positive control treatments)
NUMBER OF CELLS EVALUATED: 20000 cells/well plated for survival, viability and 6TG resistance
DETERMINATION OF CYTOTOXICITY
- Method: Cloning efficiency
OTHER: Cell viability were identified by eye using background illumination and counted; cell densities were determined using a coulter counter. - Evaluation criteria:
- For valid data, the test article was considered to induce forward mutation at the hprt locus in mouse lymphoma L5178Y cells if:
1. The mutant frequency at one or more concentrations was significantly greater than that of the negative control (p = 0.05)
2. There was a significant concentration-relationship as indicated by the linear trend analysis (p = 0.05)
3. The effects described above were reproducible.
- Results that only partially satisfied the assessment criteria described above were considered on a case-by-case basis. - Statistics:
- The experimental data was analysed using UKEMS recommended statistical guidelines.
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: No
- Effects of osmolality: No
- Evaporation from medium: No data
- Water solubility: No data;
- Precipitation: Yes; in the range-finding study, precipitation, at time of treatment, was observed at concentrations from 110 and 100 µg/mL in the absence and presence of S-9, respectively.
RANGE-FINDING/SCREENING STUDIES: Five concentrations were tested with and without S-9 ranging from 0 to 845 µg/mL (limited by solubility in culture medium).
- precipitation, at time of treatment and after incubation period, was observed at concentrations from 211.3 to 845 µg/mL and at 845 µg/mL in the absence and presence of S-9, respectively.
- Without S-9: 21% relative survival (RS) was found at 211.3 µg/mL; with S-9: highest concentration provided 6% RS
- See table 1 for more details
COMPARISON WITH HISTORICAL CONTROL DATA: Yes
ADDITIONAL INFORMATION ON CYTOTOXICITY: without S-9, 15 % RS was obtained at 150 µg/mL in the first experiment whereas 11 % RS was obtained at 110 µg/mL in the second experiment. with S-9, 16 % RS was obtained at 450 µg/mL in the first experiment and 10 % RS was obtained at 500 µg/mL in the second experiment. - Conclusions:
- Under the test conditions, propylidynetrimethyl trimethacrylate is not considered as mutagenic in L5178Y cells according to the criteria of the Annex VI to the Directive 67/548/EEC and CLP Regulation (EC) N° (1272-2008).
- Executive summary:
In an in vitro mammalian cell gene mutation test, HPRT, performed according to OECD guideline 476, in compliance with GLP, mouse lymphoma L5178Y cells were exposed to propylidynetrimethyl trimethacrylate in DMSO at concentrations of 0, 105.6, 211.3, 422.5 and 845 µg/mL in RPMI 1640 medium with and without 2% S-9 metabolic activation for a preliminary cytotoxicity test. In the main test, two experiments were performed at the following concentrations:
- Experiment 1 (3-h exposure): without S-9: 0, 30, 60, 90, 120 and 150 µg/mL; with S-9: 0, 100, 200, 250, 300, 350, 400 and 450 µg/mL
- Experiment 2 (3-h exposure): without S-9: 0, 30, 50, 70, 90 and 110 µg/mL; with S-9: 0, 100, 150, 200, 300, 350, 400, 450 and 500 µg/mL
Positive controls used to validate the experiments were benzo(a)pyrene at 2 and 3 µg/mL without metbolic activation and 4-nitroquinoline-N-oxide at 0.1 and 0.15 µg/mL with metabolic activation.
When tested up to toxic concentrations, no significant increases in mutant frequency were observed at any concentration analysed in the absence and presence of S-9 in Experiment 1 and in the presence of S-9 in Experiment 2 and there were no significant linear trends. In the absence of S-9 in Experiment 2, a small but statistically significant increase in mutant frequency was observed at the highest concentration analysed (500 µg/mL, giving 10% RS) but there was no significant linear trend. As mentioned previously, lower concentrations of 400 and 450 µg/mL gave 17% and 18% RS, respectively, but no significant increases in mutant frequency were observed at these concentrations. Furthermore, the mutant frequency value at 500 µg/mL (5.20) only marginally exceeded the historical control mean value and fell within the historical negative control ranges. Overall, the data did not fulfil all of the criteria for a positive result and the small increase in mutant frequency in the absence of S-9 in Experiment 2 was not reproduced between experiments, therefore this isolated observation was not considered biologically relevant.
Under the test conditions, propylidynetrimethyl trimethacrylate is not considered as mutagenic in L5178Y cells.
Referenceopen allclose all
Table 1: Mitotic Index Determinations - Range-Finder Experiment
Treatment | Mitotic index (%) | ||||||||
(µg/mL) | 3+17 hours, -S-9 | 3+17 hours, +S-9 | 20+0 hours, -S-9 | ||||||
| A | B | MIH* | A | B | MIH* | A | B | MIH* |
Vehicle | 7.7 | 4.8 | - | 5.9 | 3.9 | - | 1.9 | 3.8 | - |
2.902 | 4.4 | NT | 30 | NS | NT | - | NS | NT | - |
4.837 | 5.6 | NT | 10 | NS | NT | - | NS | NT | - |
8.062 | 5.9 | NT | 6 | NS | NT | - | 4.1 | NT | 0 |
13.44 | 6.0 | NT | 4 | NS | NT | - | 3.2 | NT | 0 |
22.39 | 5.4 | NT | 14 | NS | NT | - | 5.1 | NT | 0 |
37.32 | 4.3 | NT | 31 | NS | NT | - | 2.8 | NT | 2 |
62.21 | 3.3 | NT | 47 | 5.8 | NT | 0 | 2.3 | NT | 19 |
103.7 | 2.3 | NT | 63 | 5.9 | NT | 0 | 2.5 | NT | 12 |
172.8 | 3.2 | NT | 49 P | 6.3 | NT | 0 P | 2.7 | NT | 5 P |
288.0 | 1.3 | NT | 79 P | 4.2 | NT | 14 P | 1.6 | NT | 44 P |
480.0 | 0.1 | NT | 98 PEH | 4.1 | NT | 16 PE | 1.5 | NT | 47 PH |
800.0 | 0.2 | NT | 97 PEH | 1.5 | NT | 69 PE | 1.5 | NT | 47 PH |
NT = Not tested
NS = Not scored
P = Precipitation observed at treatment
E = Precipitation observed at the end of treatment incubation
H = Precipitation observed at harvest
*Mitotic inhibition (%) = [1 - (mean MI T/mean MI C)] x 100% (where T = treatment and C = negative control)
Table 2: Mitotic Index Determinations - Main experiment
Treatment (µg/mL) | Mitotic index (%) | |||||
3+17 hours, -S-9 | 3+17 hours, +S-9 | |||||
A | B | MIH* | A | B | MIH* | |
Vehicle | 9.8/6.1 | 9.2/11.3 | - | 10.2/9.0 | 12.1/10.0 | - |
10.00 | NS | NS | - | NT | NT | - |
20.00 | NS | NS | - | NT | NT | - |
40.00 | 9.7 | 10.2 | 0 | NT | NT | - |
50.00 | 10.2 | 10.7 | 0 | 11.2 | 10.5 | 0 |
60.00 | 9.9 | 9.0 | 0 P | NT | NT | - |
70.00 | 7.7 | 7.7 | 15 P | NT | NT | - |
80.00 | 7.8 | 8.5 | 10 P# | NT | NT | - |
90.00 | 7.9 | 5.7 | 25 P# | NT | NT | - |
100.0 | 4.3 | 2.9 | 60 P# | 11.9 | 11.4 | 0 P |
140.0 | 2.6 | 2.9 | 70 P | NT | NT | - |
150.0 | NT | NT | - | 11.1 | 12.1 | 0 P |
180.0 | 2.7 | 2.4 | 72 P | NT | NT | - |
200.0 | NT | NT | - | 10.4 | 9.7 | 3 P |
250.0 | 2.3 | 1.7 | 78 P | 9.4 | 9.4 | 9 P |
300.0 | NT | NT | - | 10.4 | 8.5 | 8 P |
350.0 | NT | NT | - | 9.9 | 10.3 | 2 P# |
400.0 | NT | NT | - | 10.6 | 7.2 | 14 P |
450.0 | NT | NT | - | 9.2 | 7.5 | 19 P |
500.0 | NT | NT | - | 10.0 | 9.9 | 4 P |
650.0 | NT | NT | - | 6.8 | 6.3 | 37 P# |
800.0 | NT | NT | - | 6.0 | 4.3 | 50 P# |
NS = Not scored
P = Precipitation observed at treatment
*Mitotic inhibition (%) = [1 - (mean MI T/mean MI C)] x 100% (where T = treatment and C = negative control)
# Highlighted concentrations selected for analysis
Table 3: main experiment results without S-9
Treatment (µg/mL) | Replicate | Cells Scored | Cells with Aberrations Including Gaps | Cells with Aberrations Excluding Gaps | MIH (%) |
Vehicle | A | 100 | 1 | 1 |
|
B | 100 | 2 | 1 | ||
Totals | 200 | 3 | 2 | - | |
80.00 | A | 100 | 3 | 3 |
|
B | 100 | 4 | 4 # | ||
Totals | 200 | 7 | 7 | 10 | |
90.00 | A | 100 | 2 | 2 |
|
B | 100 | 0 | 0 | ||
Totals | 200 | 2 | 2 | 25 | |
100.0 | A | 100 | 1 | 1 |
|
B | 100 | 3 | 3 | ||
Totals | 200 | 4 | 4 | 60 | |
NQO, 2.50 | A | 48 | 20 # | 19 # |
|
B | 49 | 19 # | 19 # | ||
Totals | 97 | 39 | 38a |
|
Binomial Dispersion Test ¿² = 3.19, Not significant
a Statistical significance p = 0.001
# Numbers highlighted exceed historical negative control range
Table 4: main experiment results with S-9
Treatment (µg/mL) | Replicate | Cells Scored | Cells with Aberrations Including Gaps | Cells with Aberrations Excluding Gaps | Significance § | MIH (%) |
Vehicle | A | 100 | 1 | 1 |
|
|
B | 100 | 0 | 0 | |||
Totals | 200 | 1 | 1 |
| - | |
350.0 | A | 100 | 6 # | 4 # |
|
|
B | 100 | 1 | 1 | |||
Totals | 200 | 7 | 5 | NS | 2 | |
650.0 | A | 94 | 18 # | 15 # |
|
|
B | 100 | 14 # | 13 # | |||
Totals | 194 | 32 | 28 | p = 0.001 | 37 | |
800.0 | A | 49 | 20 # | 20 # |
|
|
B | 44 | 21 # | 20 # | |||
Totals | 93 | 4 | 4 | p = 0.001 | 50 | |
CPA, 20.0 | A | 43 | 21 # | 20 # |
|
|
B | 29 | 21 # | 20 # | |||
Totals | 72 | 42 | 40 | p = 0.001 |
Binomial Dispersion Test ¿² = 3.40, NS
§ Statistical significance
NS = Not significant
# Numbers highlighted exceed historical negative control range
Table 1: RS values - range-finder experiment
Treatment (µg/mL) |
-S-9 % RS |
+S-9 % RS |
0 |
100 |
100 |
105.6 |
47 |
86 |
211.3 P, PP |
21 (P,PP) |
62 (P) |
422.5 P |
NE (P,PP) |
19 (P) |
845 P, PP |
NE (P,PP) |
6 (P,PP) |
% RS: Percentage Relative Survival
P: Precipitation observed at time of treatment
PP: Precipitation observed following treatment incubation period
NE: Not evaluated for mutant frequency due to excessive toxicity. Presented for information only
Table 2: Summary of mutation data
Experiment 1: (3 hour treatment in the absence and presence of S-9)
Treatment (µg/mL) |
-S-9 |
Treatment (µg/mL) |
+S-9 |
||||||
|
%RS |
MF§ |
|
%RS |
MF§ |
||||
0 |
|
100 |
0.21 |
|
0 |
|
100 |
2.25 |
|
30 |
|
83 |
0.58 |
NS |
100 |
P |
76 |
1.58 |
NS |
60 |
|
56 |
1.39 |
NS |
200 |
P |
50 |
2.69 |
NS |
90 |
|
35 |
0.95 |
NS |
250 |
P |
39 |
0.69 |
NS |
120 |
P |
23 |
1.41 |
NS |
300 |
P |
28 |
1.45 |
NS |
150 |
P |
15 |
0.62 |
NS |
350 |
P |
27 |
2.20 |
NS |
|
|
|
|
|
400 |
P |
25 |
1.57 |
NS |
|
|
|
|
|
450 |
P |
16 |
1.53 |
NS |
Linear trend |
NS |
Linear trend |
NS |
||||||
NQO |
|
|
|
|
B[a]P |
|
|
|
|
0.1 |
|
91 |
10.42 |
|
2 |
|
65 |
15.61 |
|
0.15 |
|
66 |
12.59 |
|
3 |
|
48 |
21.91 |
|
Experiment 2: (3 hour treatment in the absence and presence of S-9)
Treatment (µg/mL) |
-S-9 |
Treatment (µg/mL) |
+S-9 |
||||||
|
%RS |
MF§ |
|
%RS |
MF§ |
||||
0 |
|
100 |
0.94 |
|
0 |
|
100 |
1.30 |
|
30 |
|
87 |
1.61 |
NS |
100 |
P |
69 |
0.93 |
NS |
50 |
|
51 |
0.14 |
NS |
150 |
P |
60 |
2.50 |
NS |
70 |
|
35 |
0.91 |
NS |
200 |
P |
56 |
1.76 |
NS |
90 |
|
18 |
2.72 |
NS |
300 |
P |
32 |
0.80 |
NS |
110 |
P |
11 |
2.10 |
NS |
350 |
P |
30 |
0.64 |
NS |
|
|
|
|
|
400 |
P |
17 |
0.68 |
NS |
|
|
|
|
|
450 |
P |
18 |
1.85 |
NS |
|
|
|
|
|
500 |
P |
10 |
5.20 |
* |
Linear trend |
NS |
Linear trend |
NS |
||||||
NQO |
|
|
|
|
B[a]P |
|
|
|
|
0.1 |
|
38 |
28.27 |
|
2 |
|
96 |
20.03 |
|
0.15 |
|
69 |
12.60 |
|
3 |
|
79 |
38.96 |
|
§: 6-TG resistant mutants/106viable cells 7 days after treatment
%RS: Percent relative survival adjusted by post treatment cell counts
P: Precipitation observed at time of treatment
NS: Not significant
*: Comparison of each treatment with control: Dunnett's test (one-sided), significant at 5% level
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Description of key information
Two in vivo studies (in vivo micronucleus assay and in vivo/in vitro UDS assay in rat liver) showed negative results.
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From January 01 to March 22, 2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian erythrocyte micronucleus test
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: HARLAN WINKELMAN, Borchen, Germany
- Age at study initiation: 23-33 g
- Assigned to test groups randomly: Yes
- Housing: Housed in a group of 5 mice/sex in Macaroon Type III cage
- Diet (e.g. ad libitum): Pelleted standard diet (ALTROMIN, Lage/Lippe, Germany)
- Water (e.g. ad libitum): Tap water, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25
- Humidity (%): 55 ± 10
- Photoperiod (hours dark / hours light): 12 hours dark/12 hours light - Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: CMC (carboxymethyl cellulose)
- Justification for choice of solvent/vehicle: Nontoxic to animals
- Source: SIGMA, Germany
- Amount of vehicle (if gavage or dermal): 33.3 mL/kg bw
- Lot/batch no. (if required): 36H0738 - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Test material was prepared and diluted with carboxymethylcellulose.
- Duration of treatment / exposure:
- 24 hours (in all test groups) and 48 hours (in 2000 mg/kg bw group)
- Frequency of treatment:
- Once
- Post exposure period:
- Not applicable
- Remarks:
- Doses / Concentrations:
0, 200, 600 and 2000 mg/kg bw
Basis:
actual ingested - No. of animals per sex per dose:
- Five
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- CPA (cyclophosphamide)
- Source: SIGMA, Germany
- Analytical purity: At least 98%
- Route of administration: i.p.
- Doses / concentrations: 30 mg/kg bw
- Volume administered: 10 mL/kg bw
- Lot/batch no.: 087H0207 - Tissues and cell types examined:
- - Femora bones were removed for marrow extraction and the prepared slides were examined for polychromatic erythrocytes (PCEs), normochromatic erythrocytes (NCEs) and total erythrocytes
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: Dose selection was based on a preliminary range-finding test conducted on 3 mice/sex/dose at 2000 mg/kg bw. No toxic signs were recorded.
TREATMENT AND SAMPLING TIMES: Femora were removed for marrow extraction from single animals in each treatment and control group at 24 or 48 hours after exposure.
DETAILS OF SLIDE PREPARATION: Bone marrow cells extracted, preparations smeared on slides and air-dried. The slides were stained with May-Grunwald solution/ Giemsa and coded.
METHOD OF ANALYSIS: Slides were scanned using Olympus microscopes to determine the frequency of micronuclei in 2000 polychromatic erythrocytes (PCEs) per animal. In addition, PCE:NCE ratio was determined in the same sample and expressed as NCE/1000 PCEs. - Evaluation criteria:
- - Criteria for a positive response: Detection of either a statistically significant dose related increase in the number of micronucleated PCEs or a reproducible statistically significant positive response for at least one of the test points.
- Test article that does not induce both of these responses is considered negative.
- Both biological and statistical significance should be considered together. - Statistics:
- Statistical significance at the 5% level (p < 0.05) was evaluated by means of the non-parametric Mann-Whitney test.
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose: 2000 mg/kg bw
- Clinical signs of toxicity in test animals: No
RESULTS OF DEFINITIVE STUDY
- Frequency of micronuclei in polychromatic erythrocytes and PCE:NCE ratio: See table 1 - Conclusions:
- Under the test conditions, trimethylolpropantrimethacrylate is not considered as mutagenic in the mouse bone marrow micronucleus test.
- Executive summary:
In a bone marrow micronucleus test, performed according to OECD guideline 474 and in compliance with GLP, groups of NMRI mice (5/sex/dose) were given a single oral (gavage) dose of trimethylolpropantrimethacrylate in carboxymethylcellulose at doses of 0, 200, 600 and 2000 mg/kg bw. Bone marrow was extracted after 24 hours (in all test groups) or 48 hours (in 2000 mg/kg bw group) of exposure and the prepared slides were scanned to determine the frequency of micronuclei in 2000 polychromatic erythrocytes (PCEs) for each animal. In addition, PCE:NCE ratio was determined in the same sample and expressed as NCE/1000 PCEs. A preliminary range-finding test was also conducted on 3 mice/sex/dose at 2000 mg/kg bw in which no toxic signs were recorded.
No statistically significant increases in the frequency of micronucleated PCEs were observed at any dose levels. PCE:NCE ratio was slightly affected at a dose level of 2000 mg/kg bw at 24 and 48 hours indicating slight cytotoxicity of the test material. Positive control (cyclophosphamide, 30 mg/kg bw) induced the appropriate response.
Under the test conditions, trimethylolpropantrimethacrylate is not considered as mutagenic in the mouse bone marrow micronucleus test.
Reference
Table 1: Micronucleus Assay - summary table
Treatment |
Dose |
Harvest time (hours) |
% Micronucleated PCEs (mean of 2000 PCEs per animal) |
Ratio PCE:NCE (mean) |
||||
males |
females |
males |
females |
|||||
all |
small |
all |
small |
|||||
Vehicle control |
Carboxymethylcellulose 33.3 mL/kg bw |
24 |
0.16 |
0.14 |
0.16 |
0.14 |
1.14 |
1.35 |
Positive control |
Cyclophosphamide 30 mg/kg bw |
24 |
1.01 |
0.94 |
0.98 |
0.92 |
1.35 |
1.45 |
Test Article |
200 mg/kg bw |
24 |
0.18 |
0.13 |
0.14 |
0.11 |
1.19 |
0.99 |
600 mg/kg bw |
24 |
0.09 |
0.07 |
0.12 |
0.09 |
0.86 |
0.93 |
|
2000 mg/kg bw |
24 |
0.12 |
0.11 |
0.1 |
0.09 |
0.89 |
1.11 |
|
48 |
0.16 |
0.16 |
0.12 |
0.12 |
0.58 |
1.19 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Ames test (Covance, 2010) :
In a GLP study performed according to OECD guideline 471, propylidynetrimethyl trimethacrylate was tested for mutagenicity using Salmonella typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102 with the plate incorporation and preincubation methods in the presence and absence of metabolic activation system (rat S-9 mix). Due to absence of toxicity in the range-finder test, using TA100 tested at concentrations of 1.6, 8, 40, 200, 1000 and 5000 µg/plate with and without S-9, all strains in experiment 1 were tested with and without S-9 at these concentrations. In order to examine more closely those concentrations of propylidynetrimethyl trimethacrylate approaching the maximum test concentration, the following concentrations were tested in the second experiment (using the preincubation method (1h at 37°C) when S-9 was used): 156.3, 312.5, 625, 1250, 2500 and 5000 µg/plate, with and without S-9. Precipitation of the test article was observed on all test plates treated at 5000 µg/plate in the Range-Finder Experiment and Experiment 1 and at 2500 µg/plate and above in Experiment 2. In the range-finder experiment and in experiment 1, no evidence of toxicity was observed as would normally manifest as a diminution of the background bacterial lawn or a marked reduction in revertant numbers. In the second experiment, evidence of toxicity in the form of a marked reduction in revertant numbers was observed at 2500 µg/plate and above in strains TA1535 and TA1537 in the presence of S-9 and at 5000 µg/plate in strain TA1537 in the absence of S-9. The positive controls induced the appropriate responses in the corresponding strains. Propylidynetrimethyl trimethacrylate showed no substantial increases in revertant colony numbers over control count obtained with any of the tester strains at any concentrations in either presence or absence of S-9.
In vitro gene mutation test (Covance, 2010):
In the HPRT performed according to OECD guideline 476 and in compliance with GLP, mouse lymphoma L5178Y cells were exposed to propylidynetrimethyl trimethacrylate in DMSO. When tested up to toxic concentrations, no significant increases in mutant frequency were observed at any concentration analysed in the absence and presence of S-9 in Experiment 1 and in the presence of S-9 in Experiment 2 and there were no significant linear trends. In the absence of S-9 in Experiment 2, a small but statistically significant increase in mutant frequency was observed at the highest concentration analysed (500 µg/mL, giving 10% RS) but there was no significant linear trend. As mentioned previously, lower concentrations of 400 and 450 µg/mL gave 17% and 18% RS, respectively, but no significant increases in mutant frequency were observed at these concentrations. Furthermore, the mutant frequency value at 500 µg/mL (5.20) only marginally exceeded the historical control mean value and fell within the historical negative control ranges. Overall, the data did not fulfil all of the criteria for a positive result and the small increase in mutant frequency in the absence of S-9 in Experiment 2 was not reproduced between experiments, therefore this isolated observation was not considered biologically relevant. Under the test conditions, propylidynetrimethyl trimethacrylate is not considered as mutagenic in L5178Y cells.
In vitro gene mutation study in mammalian cells (Bionetics, 1979):
An old MLA/TK study was performed on TMPTMA. In this study, the test compound induced an increase in mutations at the TK locus in L5178Y mouse lymphoma cells at doses of 100 to 200 nl/ml with microsomal activation. This dose range was moderately-to-highly toxic to the cells.
This results is supposed as a false positive results, known with acrylates (Johannsen FR, Vogt B, Waite M and Deskin R (2008). Mutagenicity assessment of acrylate and methacrylate compounds and implications for regulatory toxicology programs. Reg. Toxicol. Pharmacol. 50:322-3").
In vitro chromosomal aberrations test (Covance, 2010)
In an in vitro chromosome aberration test performed according to OECD guideline 473 and in compliance with GLP, human primary lymphocytes were exposed to propylidynetrimethyl trimethacrylate dissolved in DMSO. Treatment of cells with propylidynetrimethyl trimethacrylate without S9 in the main experiment resulted in frequencies of cells with structural aberrations that were generally similar to those observed in concurrent vehicle control cultures for all concentrations analysed. Numbers of aberrant cells (excluding gaps) in treated cultures fell within the normal range with the exception of one culture at the lowest concentration analysed (80.00 µg/mL). However, the aberration frequency (excluding gaps) in the replicate culture at this concentration and at the two higher concentrations fell within the normal range; therefore this isolated observation was not considered biologically relevant. Treatment in the presence of S-9 resulted in frequencies of cells with structural aberrations that were significantly higher (p = 0.001) than those observed in concurrent vehicle control cultures at the highest two concentrations analysed (650.0 and 800.0 µg/mL). Numbers of aberrant cells (excluding gaps) exceeded the normal range in one culture at the lowest concentration analysed (350.0 µg/mL) and in both cultures at 650.0 and 800.0 µg/mL and there was clear evidence of a concentration-related response. No increases in the frequency of cells with numerical aberrations were observed with and without S9.
Under the test conditions, propylidynetrimethyl trimethacrylate was not clastogenic in human lymphocytes exposed in vitro without metabolic activation but was clastogenic in presence of metabolic activation.
In vivo micronucleus test (BSL BIOSERVICE, 2000):
In a bone marrow micronucleus test, performed according to OECD guideline 474 and in compliance with GLP, groups of NMRI mice (5/sex/dose) were given a single oral (gavage) dose of trimethylolpropantrimethacrylate in carboxymethylcellulose at doses of 0, 200, 600 and 2000 mg/kg bw. Bone marrow was extracted after 24 hours (in all test groups) or 48 hours (in 2000 mg/kg bw group) of exposure and the prepared slides were scanned to determine the frequency of micronuclei in 2000 polychromatic erythrocytes (PCEs) for each animal. In addition, PCE:NCE ratio was determined in the same sample and expressed as NCE/1000 PCEs. A preliminary range-finding test was also conducted on 3 mice/sex/dose at 2000 mg/kg bw in which no toxic signs were recorded.
No statistically significant increases in the frequency of micronucleated PCEs were observed at any dose levels. PCE:NCE ratio was slightly affected at a dose level of 2000 mg/kg bw at 24 and 48 hours indicating slight cytotoxicity of the test material. Positive control (cyclophosphamide, 30 mg/kg bw) induced the appropriate response.
Under the test conditions, trimethylolpropantrimethacrylate is not considered as mutagenic in the mouse bone marrow micronucleus test.
In vivo UDS test (RCC, 2000):
In an Unscheduled DNA Synthesis test, performed according to OECD Guideline 486 and in compliance with GLP, groups of Wistar HanIbm: WIST (SPF) male rats (4/dose) were given a single oral (gavage) dose of trimethylolpropantrimethacrylate in polyethylene glycol 400 at concentrations of 0, 500 and 2000 mg/kg bw. After a treatment period of 2 and 16 hours, primary hepatocytes cultures from three animals/dose were established in Williams medium E (WME) and exposed for 4 hours to 3HTdR (methyl-3H-thymidine). Stained triplicate cultures were examined microscopically under oil immersion and UDS was measured by automatic counter and expressed as net nuclear grain count. A preliminary range-finding test was also conducted on 2 rats at 2000 mg/kg bw. Reduction of spontaneous activity was recorded after 1 and 24 hours of exposure.
Positive controls (N,N'-Dimethylhydrazinedihydrochloride, 40 mg/kg bw and 2-acetylaminofluorene, 100 mg/kg bw) induced the appropriate responses. No dose level of the test item revealed UDS induction in the hepatocytes of the treated animals as compared to the concurrent vehicle controls.
Under the test conditions, trimethylolpropantrimethacrylate is not considered as mutagenic in UDS test.
Justification for classification or non-classification
As the positive result found in vitro in a chromosome aberration test on human lymphocytes in presence of metabolic activation was not confirmed in two in vivo tests (micronucleus assay and UDS assay ), TMPTMA is not classified according to the CLP Regulation (EC) N° 1272-2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)